Poly(ADP ribose) polymerase 1 (PARP1) inhibitors have had little clinical success. Thurber et al. used real-time in vivo single-cell pharmacokinetic imaging of a PARP1 inhibitor to show that the lack of clinical effect is probably not due to tumour cells receiving insufficient concentrations of a PARP1 inhibitor. They then used imaging data to model and predict the distribution of the PARP1 inhibitor in situations in which it would be difficult to experimentally determine pharmacokinetics, such as subcellular distribution in humans. The authors note that single-cell pharmacokinetic imaging could aid the understanding of other drugs in other diseases.
ORIGINAL RESEARCH PAPER
Thurber, G.M. et al. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nature Commun. 4, 1504 (2013)
Rights and permissions
About this article
Cite this article
Harrison, C. Single-cell imaging adds insight into drug action. Nat Rev Drug Discov 12, 264 (2013). https://doi.org/10.1038/nrd3986
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3986